Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07428447Recruiting

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Role: lead

NCT07005947Active Not Recruiting

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

Role: lead

NCT07204652Recruiting

Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis

Role: lead

NCT07217054Recruiting

Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder

Role: lead

NCT06621602Active Not Recruiting

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Role: lead

NCT05479552Active Not Recruiting

A Diagnostic Test for Dementia With Lewy Bodies

Role: lead

NCT05757206Active Not Recruiting

The Syn-Sleep Study

Role: lead

NCT04700722Completed

Synuclein-One Study

Role: lead

All 8 trials loaded